NIH-Funding

Limited Competition: Exploratory CTSA Collaborative Innovation Awards (R21 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/21/2017 - 11:18
Funding Opportunity PAR-18-245 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support highly innovative, exploratory, collaborative research projects in the NCATS Clinical and Translational Science Award (CTSA) program, with the goal of assessing utility and feasibility of proposed innovation(s).
Categories: NIH-Funding

Collaborative Innovation Award, Clinical and Translational Science Award (CTSA) Program (U01 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/21/2017 - 11:16
Funding Opportunity PAR-18-244 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite applications to stimulate innovative collaborative research in the NCATS Clinical and Translational Science Award (CTSA) consortium.
Categories: NIH-Funding

National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Addiction (U19 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/21/2017 - 11:13
Funding Opportunity PAR-18-231 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental disorders, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders; and support early stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Pre-Market Approval (PMA)-ready devices for the treatment of mental disorders, SUDs or alcohol addiction. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or SUDs or alcohol addiction, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged.
Categories: NIH-Funding

Reducing the Duration of Untreated Psychosis in the United States (R01 Clinical Trial Required)

NIH Funding Announcements - Tue, 11/21/2017 - 11:01
Funding Opportunity PAR-18-233 from the NIH Guide for Grants and Contracts. Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Compared to traditional treatment approaches, programs that integrate pharmacologic, psychological, and rehabilitation interventions for FEP, i.e., team-based Coordinated Specialty Care (CSC), have been found to produce a range of positive clinical and functional outcomes. However, the timing of treatment is critical; short and long-term outcomes are better when individuals begin treatment close to the onset of psychosis. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based services, and effective engagement in CSC are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, this Funding Opportunity Announcement (FOA) seeks research project grant applications that test practical, reproducible strategies for substantially reducing DUP among persons with FEP by eliminating bottlenecks or closing gaps in the pathway to CSC services.
Categories: NIH-Funding

Reducing the Duration of Untreated Psychosis in the United States (R34 Clinical Trial Required)

NIH Funding Announcements - Tue, 11/21/2017 - 10:52
Funding Opportunity PAR-18-232 from the NIH Guide for Grants and Contracts. Approximately 100,000 adolescents and young adults in the United States experience a first episode of psychosis (FEP) every year. The early phase of psychotic illness is widely viewed as a critical opportunity for indicated prevention, and a chance to alter the downward trajectory and poor outcomes associated with schizophrenia and related psychotic disorders. Compared to traditional treatment approaches, programs that integrate pharmacologic, psychological, and rehabilitation interventions for FEP, i.e., team-based Coordinated Specialty Care (CSC), have been found to produce a range of positive clinical and functional outcomes. However, the timing of treatment is critical; short and long-term outcomes are better when individuals begin treatment close to the onset of psychosis. Unfortunately, numerous studies find a substantial delay between the onset of psychotic symptoms and the initiation of FEP care; in the U.S. treatment is typically delayed between one and three years. Early identification of FEP, rapid referral to evidence-based services, and effective engagement in CSC are essential to shortening the duration of untreated psychosis (DUP) and pre-empting the functional deterioration common in psychotic disorders. The World Health Organization advocates reducing DUP to 3 months or less. Accordingly, this Funding Opportunity Announcement (FOA) seeks planning grant applications that (1) identify a baseline rate of DUP in community settings that include CSC programs; (2) map referral pathways to CSC care, (3) identify bottlenecks and gaps in the pathway to CSC care, and (4) develop and pilot test feasible strategies for substantially reducing DUP among persons with FEP.
Categories: NIH-Funding

National Cooperative Drug/Device Discovery/Development Groups (U01 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/21/2017 - 10:43
Funding Opportunity PAR-18-230 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to: accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders; and support early stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Pre-Market Approval (PMA)-ready devices for the treatment of mental disorders, SUDs or alcohol addiction. This FOA encourages applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or SUDs or alcohol addiction, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged.
Categories: NIH-Funding

Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/21/2017 - 10:41
Funding Opportunity PAR-18-219 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the development of medication for the treatment of Substance-Use Disorders (SUDs) by encouraging research applications to support a diverse array of preclinical and/or clinical research projects. The goal is to fund medication studies that will have high impact and quickly yield the necessary results to advance medications closer to FDA approval. It is expected that these U01s will be short-term (funded for up to 3 years) and large (up to $5 million per year) cooperative agreements with close monitoring and significant scientific involvement of NIDA staff. This funding opportunity will enable critical medications development studies that would not be feasible using the traditional R01 activity code.
Categories: NIH-Funding

Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/21/2017 - 10:38
Funding Opportunity PAR-18-218 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support research that advances compounds towards FDA approval by leveraging NIDA funds with the strengths and resources of outside organizations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, and small businesses. Applications from single entities that possess considerable resources for medications development will also be considered, provided the entity demonstrates a significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. It is anticipated that in comparison with traditional grant-funded research, strategic alliances will increase the pace at which medications to treat Substance Use Disorders (SUDs) move through the drug development process. Both the project period and budget of the grant are consistent with the objective of accelerating the pace of medications development compared to traditional research project grant funding. Project aims can range from the development of a new molecular entity to the expansion of an existing medications clinical indication(s). Each project should have a defined entry and exit point in the medications development pathway, with the objective of advancement in the FDA approval process. It is hoped that support for these collaborations will accelerate the rate of medications development for SUDs.
Categories: NIH-Funding

Human-Animal Interaction (HAI) Research (R01 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/21/2017 - 10:36
Funding Opportunity PAR-18-213 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites grant applications for research to examine 1) the impact of HAI on typical and atypical child development and health; 2) the evaluation of animal-assisted intervention for children and adults with disabilities or in need of rehabilitative services; 3) the effects of animals on public health, including cost effectiveness of involving animals in reducing and preventing disease.
Categories: NIH-Funding

Research To Address Sleep Disorders in the Context of Medical Rehabilitation (R01 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/21/2017 - 10:34
Funding Opportunity PAR-18-212 from the NIH Guide for Grants and Contracts. Patients with many disabilities report problems sleeping, but specific sleep disorders are often not diagnosed. Because sleep affects many physiological and behavioral parameters--depression, anxiety, pain, cancer, cardiovascular changes, immune function-- sleep disorders should be diagnosed and appropriately treated to maximize benefit of rehabilitation. Research is needed on ways to best approach this complexity in the context of medical rehabilitation for a primary, non-sleep disorder.
Categories: NIH-Funding

NCMRR Early Career Research Award (R03 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/21/2017 - 10:31
Funding Opportunity PAR-18-211 from the NIH Guide for Grants and Contracts. The National Center for Medical Rehabilitation Research (NCMRR) Early Career Research (ECR) Award (R03) is intended to support both basic and clinical research from rehabilitation scientists who are establishing independent research careers. It cannot be used to support thesis/dissertation research or research conducted by postdoctoral fellows. The research should be focused on one or more of the areas within the biomedical and behavioral mission of NCMRR: pathophysiology and management of chronically injured nervous and musculoskeletal systems; repair and recovery of motor and cognitive function; functional plasticity, adaptation, and windows of opportunity for rehabilitation interventions; rehabilitative strategies involving pharmaceutical, stimulation, neuroengineering approaches, exercise, motor training, and behavioral modifications; pediatric rehabilitation; secondary conditions associated with chronic disabilities; improved diagnosis, assessment, and outcome measures; and development of orthotics, prosthetics, and other assistive technologies and devices. The NCMRR ECR Award supports different types of projects including secondary analysis of existing data; small, self-contained research projects; development of research methodology; translational research; outcomes research; and development of new technology. Irrespective of the type of project, the intent of the NCMRR ECR Award is for the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) to obtain sufficient preliminary data for a subsequent R01 application.
Categories: NIH-Funding

Planning Grants for Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care (R34 Clinical Trial Required)

NIH Funding Announcements - Tue, 11/21/2017 - 10:23
Funding Opportunity PAR-18-107 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to develop and pilot test approaches to improve diabetes and obesity prevention and/or treatment that are adapted for implementation in healthcare settings where individuals receive routine medical care. Research applications should be designed to pilot test practical and sustainable strategies to improve processes of care and health outcomes for individuals with or at risk of diabetes and/or obesity. The goal is that, if the pilot study shows promising results, the data from the R34 will be used to support a full-scale trial focused on improving routine healthcare practice and informing healthcare policy for the prevention or management of diabetes and obesity.
Categories: NIH-Funding

Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care (R18 Clinical Trial Required)

NIH Funding Announcements - Tue, 11/21/2017 - 10:18
Funding Opportunity PAR-18-106 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to test innovative approaches to improve diabetes and obesity prevention and/or treatment that are adapted for implementation in healthcare settings where individuals receive their routine medical care. Research applications should be designed to test practical and sustainable strategies to improve processes of care and health outcomes for individuals with or at risk of diabetes and/or obesity. The research should also focus on approaches that can be broadly disseminated outside the specific setting where it is being tested. The goal of the research is to obtain results that will improve routine healthcare practice and inform healthcare policy for the prevention or management of these conditions. Therefore, interventions must be integrated into the existing healthcare structure and/or processes; the healthcare setting may not be used solely as a venue for recruitment.
Categories: NIH-Funding

Ancillary Studies to Identify Behavioral and/or Psychological Phenotypes Contributing to Obesity (R01 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/21/2017 - 10:12
Funding Opportunity PAR-18-105 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications to support the addition of measures of psychological and/or behavioral constructs or weight-related variables (e.g.; BMI, body composition) to existing or new research studies in humans with the goal of elucidating behavioral or psychological phenotypes that explain individual variability in weight trajectory or response to obesity prevention or treatment interventions. The intent is to support the addition of new measurement in domains other than those covered in the parent grant as a means of elucidating the behavioral and psychological factors that may explain individual differences in weight status. For the purposes of this FOA, behavioral factors related to energy intake include overt actions/behavior (e.g.; objective observation of eating event including measures such as quantity, selection/quality, and speed of intake) and underlying psychological processes related to self-regulation of intake such as cognitive control, affective response, learning, and motivation. The rationale is that an improved understanding of the individual characteristics and processes that explain energy intake patterns can lead to better matching of individuals to prevention or treatment approaches and identify novel targets for more efficacious individual and population level approaches to weight management.
Categories: NIH-Funding

NCI Small Grants Program for Cancer Research (NCI Omnibus R03 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/21/2017 - 10:11
Funding Opportunity PAR-18-021 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.
Categories: NIH-Funding

Elucidating HIV and HIV-treatment Associated Metabolic/Endocrine Dysfunction (R01 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/21/2017 - 09:55
Funding Opportunity RFA-DK-17-036 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to support innovative research to elucidate the role of HIV infection, including relevant host conditions or antiretroviral therapy, on metabolic and endocrine dysfunction, as well as to support innovative research delineating the pathophysiology, etiology, risk or protective factors, and potential strategies to prevent, treat, or reverse endocrine and metabolic dysfunction in HIV-infected individuals. This FOA supports both mechanistic research and clinical trials. Proposed projects must be related to the mission of the Division of Diabetes, Endocrinology, and Metabolic Diseases within NIDDK (DEM/NIDDK).
Categories: NIH-Funding

The Role of the Microbiome in the Developmental Origins of Health and Disease (DOHaD) (R01 Clinical Trial Not Allowed)

NIH Funding Announcements - Tue, 11/21/2017 - 09:25
Funding Opportunity RFA-ES-18-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks innovative research proposals that use animal models to investigate the potential role of the microbiome in mediating the latent effects of early life exposure.
Categories: NIH-Funding

mHealth Tools for Individuals with Chronic Conditions to Promote Effective Patient-Provider Communication, Adherence to Treatment and Self-Management (R21 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/21/2017 - 04:34
Funding Opportunity PA-18-389 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to stimulate research utilizing Mobile Health (mHealth) tools aimed at the improvement of effective patientprovider communication, adherence to treatment and self-management of chronic diseases. With the rapid expansion of cellular networks and substantial advancements in Smartphone technologies, it is now possible - and affordable - to transmit patient data digitally from remote areas to specialists in urban areas, receive real-time feedback, and capture that consultation in a database. These mHealth tools, therefore, may facilitate more timely and effective patient-provider communication through education communication around goal setting, treatment reminders, feedback on patient progress, and may improve health outcomes. This announcement encourages the development and testing of interventions utilizing mHealth technologies. There is also an interest in studying mHealth technologies in underserved populations.
Categories: NIH-Funding

mHealth Tools for Individuals with Chronic Conditions to Promote Effective Patient-Provider Communication, Adherence to Treatment and Self-Management (R01 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/21/2017 - 04:27
Funding Opportunity PA-18-386 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to stimulate research utilizing Mobile Health (mHealth) tools aimed at the improvement of effective patientprovider communication, adherence to treatment and self-management of chronic diseases. With the rapid expansion of cellular networks and substantial advancements in Smartphone technologies, it is now possible - and affordable - to transmit patient data digitally from remote areas to specialists in urban areas, receive real-time feedback, and capture that consultation in a database. These mHealth tools, therefore, may facilitate more timely and effective patient-provider communication through education communication around goal setting, treatment reminders, feedback on patient progress, and may improve health outcomes. This announcement encourages the development and testing of interventions utilizing mHealth technologies. There is also an interest in studying mHealth technologies in underserved populations.
Categories: NIH-Funding

Family-Centered Self-Management of Chronic Conditions (R21 Clinical Trial Optional)

NIH Funding Announcements - Tue, 11/21/2017 - 03:48
Funding Opportunity PA-18-380 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage research that seeks to build the science of family-centered self-management (FCSM) in chronic conditions.
Categories: NIH-Funding